SEARCH

SEARCH BY CITATION

References

  • Abraham SM, Clark AR (2006). Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34: 10181023.
  • Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J et al. (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 18831889.
  • Barnes PJ (2006). Corticosteroids: the drugs to beat. Eur J Pharmacol 533: 214.
  • Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K (2009). Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 30: 830882.
  • Berlin M (2010). Recent advances in the development of novel glucocorticoid receptor modulators. Expert Opin Ther Pat 20: 855873.
  • Bladh LG, Johansson-Haque K, Rafter I, Nilsson S, Okret S (2009). Inhibition of extracellular signal-regulated kinase (ERK) signaling participates in repression of nuclear factor (NF)-kappaB activity by glucocorticoids. Biochim Biophys Acta 1793: 439446.
  • Cavet ME, Harrington KL, Ward KW, Zhang JZ (2010). Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis 16: 17911800.
  • Chen W, Rogatsky I, Garabedian MJ (2006). MEDI14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endoncrinol 20: 560572.
  • Chivers JE, Gong W, King EM, Seybold J, Mak JC, Donnelly LE et al. (2006). Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 70: 20842095.
  • Cho IJ, Kim SG (2009). A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR. Mol Endocrinol 23: 8699.
  • Clark AR (2007). Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 275: 7997.
  • Coghlan MJ, Elmore SW, Kort ME, Kym PR, Moore JL, Pratt JK et al. (1999). Preparation of glucocorticoid-selective anti-inflammatory agents. Patent WO99041256.
  • De Bosscher K, Haegeman G, Elewaut D (2010). Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10: 497504.
  • Diefenbacher M, Sekula S, Heilbock C, Maier JV, Litfin M, van Dam H et al. (2008). Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol 22: 17671780.
  • Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13: 925931.
  • Frijters R, Fleuren W, Toonen EJ, Tuckermann JP, Reichardt HM, Van der Maaden H et al. (2010). Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 11: 359.
  • Furst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S et al. (2007). MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 21: 7480.
  • Galliher-Beckley AJ, Cidlowski JA (2009). Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 61: 979986.
  • Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA (2008). Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28: 73097322.
  • Glass CK, Saijo K (2010). Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 10: 365376.
  • Gupta V, Galante A, Soteropoulos P, Guo S, Wagner BJ (2005). Global gene profiling reveals novel glucocorticoid induced changes in gene expression of human lens epithelial cells. Mol Vis 11: 10181040.
  • Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato A et al. (2006). Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 203: 1520.
  • Hillier SG (2007). Diamonds are forever: the cortisone legacy. J Endocrinol 195: 16.
  • Holden NS, Gong W, King EM, Kaur M, Giembycz MA, Newton R (2007). Potentiation of NF-κB-dependent transcription and inflammatory mediator release by histamine in human airway epitheial cells. Br J Pharmacol 152: 891902.
  • Hudson AR, Roach SL, Higuchi RI (2008). Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs). Curr Top Med Chem 8: 750765.
  • Humphrey EL, Williams JH, Davie MW, Marshall MJ (2006). Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38: 652661.
  • Issa R, Xie S, Khorasani N, Sukkar M, Adcock IM, Lee KY et al. (2007). Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J Immunol 178: 73667375.
  • Janka-Junttila M, Moilanen E, Hasala H, Zhang X, Adcock I, Kankaanranta H (2006). The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. J Inflamm (Lond) 3: 1–10.
  • Jaroch S, Lehmann M, Schmees N, Buchmann B, Rehwinkel H, Droescher P et al. (2002). Preparation of amido-benzoxazinone/phthalides as non-steroidal inflammation inhibitors. Patent WO02010143.
  • Johansson-Haque K, Palanichamy E, Okret S (2008). Stimulation of MAPK-phospatase 1 (MKP-1) gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP. J Mol Endocrinol 41: 239249.
  • John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA et al. (2011). Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 43: 264268.
  • Kang BN, Jude JA, Panettieri RA, Jr, Walseth TF, Kannan MS (2008). Glucocorticoid regulation of CD38 expression in human airway smooth muscle cells: role of dual specificity phosphatase 1. Am J Physiol Lung Cell Mol Physiol 295: L186L193.
  • Kassel O, Herrlich P (2007). Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects. Mol Cell Endocrinol 275: 1329.
  • King EM, Holden NS, Gong W, Rider CF, Newton R (2009). Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284: 2680326815.
  • Kleiman A, Tuckermann JP (2007). Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 275: 98108.
  • Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD et al. (2003). Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem 46: 10161030.
  • Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ et al. (2007). Macrophage lineage phenotypes and osteoclastogenesis – complexity in the control by GM-CSF and TGFβ. Bone 40: 323326.
  • Lasa M, Brook M, Saklatvala J, Clark AR (2001). Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 21: 771780.
  • Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR (2002). Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22: 78027811.
  • Li F, Zhang M, Hussain F, Triantaphyllopoulos K, Clark AR, Bhavsar PK et al. (2010). Inhibition of p38-MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 37: 933942.
  • Lopez FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S et al. (2008). LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 149: 20802089.
  • Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR (2009). DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324: 407410.
  • Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE et al. (2007). Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 104: 1924419249.
  • Newton R (2000). Molecular mechanisms of glucocorticoid action: what is important? Thorax 55: 603613.
  • Newton R, Holden NS (2007). Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72: 799809.
  • Newton R, Leigh R, Giembycz MA (2010). Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 125: 286327.
  • Owens DM, Keyse SM (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 32033213.
  • Pfeffer BA, DeWitt CA, Salvador-Silva M, Cavet ME, Lopez FJ, Ward KW (2010). Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids. Invest Ophthalmol Vis Sci 51: 437446.
  • Quante T, Ng YC, Ramsay EE, Henness S, Allen JC, Parmentier J et al. (2008). Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 39: 208217.
  • Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B et al. (2010). Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 11: 517531.
  • Reddy TE, Pauli F, Sprouse RO, Neff NF, Newberry KM, Garabedian MJ et al. (2009). Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res 19: 21632171.
  • Schacke H, Docke WD, Asadullah K (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 2343.
  • Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N et al. (2004). Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101: 227232.
  • Schacke H, Berger M, Rehwinkel H, Asadullah K (2007). Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275: 109117.
  • Schacke H, Zollner TM, Docke WD, Rehwinkel H, Jaroch S, Skuballa W et al. (2009). Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158: 10881103.
  • Shafiee A, Bucolo C, Budzynski E, Ward KW, Lopez FJ (2010). In vivo ocular efficacy profile of BOL-303242-X, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 52: 14221430.
  • Shipp LE, Lee JV, Yu CY, Pufall M, Zhang P, Scott DK et al. (2010). Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS ONE 5: e13754.
  • Smoak K, Cidlowski JA (2006). Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 26: 91269135.
  • So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR (2007). Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3: e94.
  • Tchen CR, Martins JR, Paktiawal N, Perelli R, Saklatvala J, Clark AR (2010). Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J Biol Chem 285: 26422652.
  • Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P (1999). The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 147: 13651370.
  • Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM (2005). Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci 42: 71104.
  • Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C et al. (1997). Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11: 12451255.
  • Wang X, Nelin LD, Kuhlman JR, Meng X, Welty SE, Liu Y (2008). The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia. Life Sci 83: 671680.
  • Zhang JZ, Cavet ME, VanderMeid KR, Salvador-Silva M, Lopez FJ, Ward KW (2009). BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis 15: 26062616.